Dapagliflozin Tablet 10 mg ,Originator Dapagliflozin Tablet 10 mg
Sponsors
Bio-innova Co., Ltd.
Conditions
Healthy volunteers, A Bioequivalence safety study
Bioequivalence Dapagliflozin Tablet 10 mgThe study is conducted in healthy Thai human volunteers to improve glycemic
Bioequivalence Dapagliflozin Tablet 10 mg
Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Dapagliflozin Tablet 10 mg relative to Originator Dapagliflozin Tablet 10 mg in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20250604001
Start: 2025-10-10Target: 42Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Dapagliflozin Tablet 10 mg relative to Originator Dapagliflozin Tablet 10 mg in healthy Thai participants under fasting condition
Active, not recruitingTCTR20251212001
Start: 2026-05-19Target: 30Updated: 2026-08-03